objective Multidrug-resistant tuberculosis (MDR-TB) has been a major threat for successful TB control. We examined the relationship between social support and treatment outcomes in MDR-TB patients and evaluated barriers to social support.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is a major barrier to successful TB control. WHO estimated that globally there were 480 000 new MDR-TB cases in 2015 [1] . Patients with MDR-TB often experience a long and complicated treatment regimen, serious adverse drug reactions and a high economic burden, resulting in poor adherence and a low treatment success rate [2, 3] . To address these problems, WHO recommended to provide a series of community-based social supports as well as Directly observed therapy (DOT) to MDR-TB patients. Social support is defined as a process of interaction in relationships which improves coping, esteem, belonging and competence through actual or perceived exchanges of physical or psychosocial resources [4] . It is often classified into tangible support (e.g. financial), informational support (e.g. health education), emotional support (e.g. psychological support) and appraisal support [5] . DOT is a strategy to improve medication adherence by supervising patients taking TB medicines [6] . DOT is also recognised as a special type of social support [7, 8] .
China has the second-largest MDR-TB burden in the world. The Global Fund targeted at MDR-TB control at the national level (referred to hereafter as 'GF programme') introduced the first standardised 24-month regimen in China in October 2008 [9] , which involved taking one intravenous second-line TB drug in the first 6 months and four oral second-line TB drugs over the whole treatment period. Typically, patients were initially hospitalised for about two months. After discharge, they visited prefectural-level TB-designated hospitals monthly for laboratory examinations and medicine refills. The costs of TB drugs and laboratory examinations were covered by the GF programme. During the remaining 22 months, patients were managed at the community level. A community health worker, normally a village doctor, was assigned as the treatment supporter. From 2008 to mid-2014, more than 9000 MDR-TB patients were enrolled in the GF programme and two-thirds of them reached sputum culture conversion at the end of 6 months of treatment [10, 11] . Despite these achievements, China still faces formidable challenges in MDR-TB control. In 2013, only 16% of the estimated MDR-TB cases were identified and only 10% received highquality treatment [12] . The treatment success rate for MDR-TB is low in China, ranging from 42% to 53% [13, 14] . Lack of social support for TB patients has been reported as a barrier to effective treatment [15, 16] .
There is little evidence on the effect of social support in improving MDR-TB treatment outcomes [15, [17] [18] [19] . Social support is important in low-and middle-income countries, where MDR-TB demands considerable social resources. We generated a theoretical framework based on the social support theory (Figure 1 ) to explore the relationship between the two. Generally, social support may have positive effects on health outcomes through three pathways: physical, behavioural or physiological mechanisms [20] . In the physical pathway, social support may directly influence individuals' susceptibility to illnesses through acting on endocrine and immune system and then affect health outcomes [21] . In the behavioural pathway, social support may propel recipients to perform or maintain a certain health behaviour that would directly improve their health outcomes [22] . In the physiological pathway, social support is assumed to improve health through reducing negative effects caused by stressors. Our study focused on the physical (direct) and behavioural (indirect) effects of social support on outcomes, namely on measuring the relationship between social support and treatment outcomes of patients with MDR-TB and on testing whether medication adherence mediates the association between social support and treatment outcomes. The second objective was to evaluate the implementation of, and barriers to, social support strategies from patients' perspectives.
Materials and methods

Study design and setting
From August to October 2014, we conducted a retrospective cohort study in Zhejiang, China. Zhejiang is located in the east of China and has a population of 49 million. Per capita GDP was $11 890 ($1 equals RMB 6.14 in 2014) in 2014. Zhejiang implemented the GF programme in five of 11 cities, covering a population of 21 million. All GF project sites were included. A mix of quantitative and qualitative study methods was used, which helps to reflect the issues under study from different perspectives: we collected quantitative data to measure the relationship between social support and treatment outcomes, and qualitative data to better understand the barriers to social support.
Social support strategies in Zhejiang
The GF programme requested DOT be delivered to all patients for the full course of treatment at the community level. DOT providers were to visit patients every day and provide health education. Patients living in poverty were provided with RMB60/US$10 per month as transportation costs by the GF programme. Psychological support was mandatory and it was suggested that it be delivered by psychologists or other health-care workers who were professionally trained in counselling (Table 1) [23] .
Participants
The sample size for the quantitative study was calculated based on the estimated impact of DOT on MDR-TB treatment outcomes. Based on previous studies [15, 18] , we assumed that 50% of patients are treated under DOT and that the treatment success rate for patients who received DOT is 67% vs. 47% for patients who selfadministered. To achieve 80% study power at a 5% level of significance, a minimum of 204 participants were needed. We included all MDR-TB patients in the GF project, as the total was 403. Patients were recruited based on the following criteria: (i) had laboratory-confirmed MDR-TB by solid culture and drug susceptibility testing; (ii) started treatment between 1 January 2009 and 30 June 2012; and (iii) enrolled in the GF programme during the study period. Exclusion criteria were (i) severe complications such as cancers, HIV or severe lung diseases requiring surgery or an adjusted treatment regimen; and (ii) XDR-TB.
The interviewed community health workers had to be appointed treatment supporters and supervisors of at least one MDR-TB patient during the study period. The interviewed patients had to (i) meet the inclusion criteria for participants; (ii) include patients who were cured, who had completed treatment, who had defaulted and who had interrupted treatment.
Data collection
All data were collected between August and October 2014. We invited eligible patients for a 30-to 45-min face-to-face questionnaire interview. A structured questionnaire validated in a previous study [15] was employed to collect information on demographic characteristics, medication adherence, social support received and patients' self-reported social support. We assessed the self-reported social support using the Social Support Rating Scale (SSRS) [24] , which comprises 10 items and is widely used for measuring social support among patients with chronic diseases in China. Patients were surveyed either at local Community Healthcare Centers (CHCs) or at home and were compensated with $8.1 for travel cost. Their medical records, which contained information on clinical characteristics and treatment outcomes, were photocopied at the prefectural TB-designated hospital. Medication adherence was measured using interruption, which refers to any time throughout the entire treatment period that a patient missed a prescribed dose of MDR-TB treatment for at least two weeks but less than two consecutive months. The definitions and classifications of treatment outcomes were in accordance with WHO's guideline [25] . Cure and treatment completion were combined into successful treatment outcomes, whereas death, treatment failure and default were combined into unsuccessful treatment outcomes.
In-depth interviews were to be conducted with 10 treatment supporters and 10 MDR-TB patients or until data reached saturation. Topics covered were any social support provided and received during treatment, treatment supporters' and patients' attitudes towards social support, barriers and suggestions regarding social support. A group of undergraduate students from Zhejiang Normal University conducted the questionnaire survey. Research team members, comprising PhD students and experts on public health, health policy and management were responsible for collecting qualitative data.
Data analysis
Quantitative data were analysed using Stata 13.1 (StataCorp LP, Texas, USA) or Mplus (Muth en & Muth en, Los Angeles, USA) where appropriate. All variables were described using descriptive analysis, such as mean, standardised deviation and percentage. Chi-square and independent-samples t-test were used to compare the differences in interruption rate and treatment success rate between patients with different characteristics or receiving different social supports. Binary logistic regressions and generalised linear regressions were employed to estimate factors associated with social support. To test whether medication adherence mediated the association between social support and treatment success, we performed pathway analysis. Pathway analysis is a special case of structural equation modelling used to estimate the direct or indirect effect via the mediating factor of a variable on the outcome. The chi-square difference test comparing nested models was used to measure its model fit, and a P-value >0.05 signified that the hypothesised model fit the data well.
Qualitative data were transcribed verbatim and imported into ATLAS.ti software (Scientific Software Development, Berlin, Germany). A framework approach was employed to analyse the data. The transcripts were carefully scrutinised by two researchers and then coded according to emerging and recurrent keywords. Relevant codes were merged into categories and then major themes were extracted from the categories.
Quality control
Before the main study, we conducted a pilot study in one city of Zhejiang, to shape and refine our questionnaire and interview guide. Two collection supervisors who were members of the research team were responsible for ensuring the quality of the collected data. Quantitative data were double-checked and qualitative data were peerreviewed; incomplete or unclear points were followed-up with interviewees or informants. 
Ethical approval
Results
Quantitative study
Background characteristics of all participants. Of the 403 patients enrolled in the GF programme, 76% met the inclusion criteria. Of these 307 eligible patients, 218 (71%) participated in our study (Figure 2 ). Of the responders, 70% were male and the median age was 44 years. A total of 59 (27%) participants interrupted treatment at least once. Compared to younger or bettereducated patients, older (P = 0.02) or less educated patients (P = 0.045) were more likely to interrupt therapy. Two-thirds of the participants (66%) reached successful treatment outcomes. Those who were younger (P = 0.023) had a higher level of education (P = 0.04) and were treated with a standardised treatment regimen (P = 0.04) had a higher treatment success rate (Table 2 ).
Social support received by patients. Less than half of participants (45%) were on DOT; 62% of the DOT providers were family members. Most participants received financial support (54%) and disease-related health education (80%) during their treatment, but none reported receiving psychological support. The mean score for self-reported total social support was 32.4 (SD = 7.6). Self-administering patients reported a higher interruption rate than those on DOT (P = 0.009). Compared to those who self-administered did not receive financial support and reported less social support, patients on DOT (P = 0.02), who received financial support (P < 0.001) and reported more social support (P = 0.02), had a significantly higher treatment success rate (Table 3) .
Relationship between social support, medication adherence and treatment outcomes. The pathway model revealed a good model fit (v 2 = 20.275, P = 0.06). We found that (1) financial support (b = 0.769, SE = 0.210, P < 0.001), self-reported social support (b = 0.031, SE = 0.015, P = 0.04) and medication adherence (b = 0.538, SE = 0.151, P < 0.001) significantly predicted positive direct effect on treatment success; (2) DOT significantly predicted a positive direct effect on medication adherence (b = 0.541, SE = 0.203, P = 0.008) and (3) financial support had a positive direct effect with selfreported social support (b = 2752, SE = 1.055, P = 0.009) ( Table 4) . As shown in Figure 3 , the effect of DOT on treatment success was mediated by medication adherence. Financial support had both a positive direct effect and an indirect effect via self-reported social support on treatment success.
Qualitative study
Background characteristics. Of the 10 interviewed treatment supporters, six were male. Supporters had a median age of 39 (range 28-50). Six of the ten were general practitioners and the others were public health physicians. During the study time, half of these supporters were supervising one patient, three were supervising two and the other two were supervising three.
Seven of the 10 interviewed patients were male. Patients had a median age of 46 (range 27-64). Half of them had completed treatment, two defaulted and three failed. Three patients interrupted treatment.
Poor-quality DOT and negative attitudes. DOT was mainly offered by family members without specific DOT training. Moreover, the quality of DOT performance was insufficient. 'The doctor just told my wife to watch me swallowing my drugs . . . I guess that <20% of all my doses were under her observation.
[patient, male, 45 years]'. Treatment supporters and patients both held negative attitudes towards the provision of DOT. Most interviewed treatment supporters described DOT as 'burdensome work or 'an impossible task'. Almost all of them were reluctant to provide DOT, although they received an allowance of $163-326 per patient per year. Reasons for their reluctance were (i) afraid of being infected; (ii) workload too heavy due to lack of health personnel; (iii) most patients and their families were against DOT. 'If I had the option, I would not do that work, mainly because I worry about being infected. . . of patients, many were unwilling to receive DOT because they feared disclosing their TB status to others or they thought DOT was a waste of time. 'They had better follow me up via phone call than visit me at home. I don't want to let the neighbours know my disease [patient, female, 37 years]'. *Chi-square was used to compare the difference between interrupted and not interrupted, successful treatment outcomes and unsuccessful treatment outcomes regarding background variables.
The bold values mean there is a significant difference between two groups, using P < 0.05 as the significant threshold.
Financial support delivered arbitrarily. Although the majority of the medical expenditures were covered by the GF programme, many patients still experienced high economic burden. One defaulted patient reported: 'I had resigned and had no income at that time. But I had to pay for the treatment and to live' (Patient, male, 39 years). However, financial support was provided to those subjectively judged as poor. 'We provided financial support based on patients' economic statuses. I don't think a patient who has a Benz needs the money [Treatment supporter, male, 32 years]'.
Psychological support was not available. Many patients suffered from psychological burden. On the one hand, professional psychological aid was unavailable; on the other hand, lack of family support may lead to adverse outcomes. A treatment supporter told the story that impressed him most: 'The biggest problem, in my opinion, is the huge psychological burden, from themselves and their families. I remembered a patient from Sichuan province who was highly adherent to his therapy. I believed that he would be cured if he had finished 2-year treatment. But in his second year, his wife divorced him. He had no relatives or friends in Hangzhou, so he discontinued his treatment and went back to his hometown. He has died now [treatment supporter, male, 32 years]'. Patients also reported their desire for accessing psychological support: 'I did expect that someone would give DOT, directly observed therapy; SAT, self-administration therapy. *Chi-square was used to compare the difference between interrupted and not interrupted, successful treatment outcomes and unsuccessful treatment outcomes regarding social support the participants received. †Independent-samples t-test was used to compare the difference between interrupted and not interrupted, successful treatment outcomes and unsuccessful treatment outcomes regarding self-reported social support scale. ‡Interrupted patients/not interrupted participants. §Participants with successful treatment outcomes/participants with unsuccessful treatment outcomes.
The bold values mean there is a significant difference between two groups, using P < 0.05 as the significant threshold. 
Discussion
Our main findings are that DOT significantly improved treatment success in patients with MDR-TB through its effects on medication adherence. However, the DOT rate was low with related poor performance and most DOT providers were family members. Financial support had a strong positive effect on treatment success, and an indirect positive effect on treatment success through self-reported social support. Psychological support, although perceived as an important strategy to improve treatment outcomes, was missing at community level. No relationship was found between health education and treatment outcomes. DOT is regarded as a timely reminder and could improve medication adherence by providing psychological comfort to patients [26] . In terms of the effectiveness of DOT, systematic reviews reveal a positive relationship between DOT and treatment outcomes in MDR-TB patients [18, 27] . However, DOT may be of such low quality that it has no beneficial effect [6, 28] . Moreover, it may reveal patient status and attract stigma, while imposing extra burdens on vulnerable patients through travel to a DOT place [29, 30] . Treatment supporters may fear being infected; indeed the risk of TB infection is significantly higher in health-care workers than the general population [31] . Public health tasks, which are paramount to village doctors, leave them with less time and interest to provide DOT.
As an incentive to therapy adherence, financial support is strongly related to treatment outcome. MDR-TB is a disease of the poor [32] . Although the costs of TB drugs and laboratory tests were covered by the GF programme, patients still face heavy economic burden owing to the high living costs in large cities and expensive auxiliary medicines [33] . Transport and nutritional support provided by the GF programme in cash is beneficial, but has to be given in a way that is sensitive to patient's needs [34, 35] . However, we did not find any relationship between financial support and medication adherence as expected -perhaps because patients' economic status was subjectively evaluated by treatment supporters. Without standards, some of those in great financial need may not receive support and may not adhere to treatment well.
Psychological burden is common among patients with TB, mainly due to TB stigma or patients' fear of treatment failure [36, 37] . To reduce this burden, some countries provide psychological interventions to MDR-TB patients and have observed positive effects [38, 39] . In our study, neither was psychological support provided to patients by health-care workers, nor did participants take the initiative in seeking it. Partly this was due to lack of training, guidelines or psychological experts in the community; also patients with little medical knowledge may not be aware of their need for psychological support. Our study has several strengths. First, the cohort study in Zhejiang fills a gap in that there has been none examining the impact of social support on treatment outcomes in patients with MDR-TB. Second, the cohort study is a limited research study on a large number of patients with MDR-TB in China. Third, the findings of this study, both theoretically and practically, shed light on how to tailor interventions to improve effective MDR-TB care in China and developing countries.
Our study also has limitations. First, it lacks the capacity to distinguish the effect of other factors, for example, environmental or genes, that may also play a role in affecting treatment outcomes. Second, there maybe recall bias due to the nature of the retrospective and self-reporting study design. Third, those who died or were lost to follow-up were not included, which may cause selection bias. Fourth, the majority of patients received health education, even those not assigned to a health education group received it at the beginning of treatment. That may be the cause of the non-correlation between health education and outcomes. Future studies which evaluate the quality of health education for patients with MDR-TB and examine the dose relationship between health education and adherence are suggested. Finally, our study was conducted in a relatively rich province of China, which may limit the generalisability of its results.
We suggest that well-trained family members or private providers would be better DOT providers than healthcare workers. Standards for evaluating economic status should be established to maximise the efficacy of financial support. Guidelines on giving psychological support and training for community health workers would be helpful. To detect patients with psychological disorders and enable early intervention, patients should be psychologically assessed regularly. The smallness of incentives may have reduced community health workers' motivation. The quality of MDR-TB care in the community may be improved by integrating social support with general practitioner services and pay for performance in the new health-care system reform of China.
